Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.

被引：6
|
作者：
Boileve, Alice
Baiev, Islam
Dinicola, Caroline
Horick, Nora K.
Tazdait, Melodie
Zhu, Andrew X.
Hollebecque, Antoine
Goyal, Lipika
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Gustave Roussy, Med Imaging, Villejuif, France
[4] Massachusetts Gen Hosp, Ctr Canc, Harvard Med Ctr, Boston, MA USA
[5] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4084
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The landscape of genetic alterations in ameloblastomas relates to clinical features
    Sibel Elif Gültekin
    Reem Aziz
    Carina Heydt
    Burcu Sengüven
    Joachim Zöller
    Ali Farid Safi
    Matthias Kreppel
    Reinhard Buettner
    Virchows Archiv, 2018, 472 : 807 - 814
  • [42] The landscape of genetic alterations in ameloblastomas relates to clinical features
    Gultekin, Sibel Elif
    Aziz, Reem
    Heydt, Carina
    Senguven, Burcu
    Zoller, Joachim
    Safi, Ali Farid
    Kreppel, Matthias
    Buettner, Reinhard
    VIRCHOWS ARCHIV, 2018, 472 (05) : 807 - 814
  • [43] CLINICAL, MOLECULAR AND RADIOLOGICAL FEATURES OF FGFR-TACC POSITIVE GLIOMAS
    Di Stefano, Anna Luisa
    Savatovsky, Julien
    Bielle, Franck
    Alentorn, Agusti
    Picca, Alberto
    Saragoussi, Edouard
    Villa, Chiara
    Farina, Patrizia
    Lasorella, Anna
    Iavarone, Antonio
    Sanson, Marc
    NEURO-ONCOLOGY, 2017, 19 : 173 - 173
  • [44] Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma.
    Abou-Alfa, Ghassan K.
    Bibeau, Kristen
    Schultz, Nikolaus
    Yaqubie, Amin
    Millang, Brittanie M.
    Ren Haobo
    Feliz, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [45] Evaluation of clinical, laboratory, and molecular genetic features of patients with biotinidase deficiency
    Yilmaz, Begum
    Ceylan, Ahmet Cevdet
    Gunduz, Mehmet
    Uzun, Ozlem unal
    Yavas, Aynur Kucukcongar
    Gurbuz, Berrak Bilginer
    Oncul, Ummuhan
    Ceylan, Gulay Gulec
    Kasapkara, cigdem Seher
    EUROPEAN JOURNAL OF PEDIATRICS, 2024, 183 (03) : 1341 - 1351
  • [46] Evaluation of clinical, laboratory, and molecular genetic features of patients with biotinidase deficiency
    Begüm Yılmaz
    Ahmet Cevdet Ceylan
    Mehmet Gündüz
    Özlem Ünal Uzun
    Aynur Küçükcongar Yavaş
    Berrak Bilginer Gürbüz
    Ümmühan Öncül
    Gülay Güleç Ceylan
    Çiğdem Seher Kasapkara
    European Journal of Pediatrics, 2024, 183 : 1341 - 1351
  • [47] Clinical and molecular genetic features of cerebrotendinous xanthomatosis patients in Chinese families
    Chen Chen
    Yue Zhang
    Hui Wu
    Yi-Min Sun
    Ye-Hua Cai
    Jian-Jun Wu
    Jian Wang
    Ling-Yun Gong
    Zheng-Tong Ding
    Metabolic Brain Disease, 2017, 32 : 1609 - 1618
  • [48] Clinical and molecular genetic features of cerebrotendinous xanthomatosis patients in Chinese families
    Chen, Chen
    Zhang, Yue
    Wu, Hui
    Sun, Yi-Min
    Cai, Ye-Hua
    Wu, Jian-Jun
    Wang, Jian
    Gong, Ling-Yun
    Ding, Zheng-Tong
    METABOLIC BRAIN DISEASE, 2017, 32 (05) : 1609 - 1618
  • [49] Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression
    Morizane, Chigusa
    Ueno, Makoto
    Ioka, Tatsuya
    Tajika, Masahiro
    Ikeda, Masafumi
    Yamaguchi, Kensei
    Hara, Hiroki
    Yabusaki, Hiroshi
    Miyamoto, Atsushi
    Iwasa, Satoru
    Muto, Manabu
    Takashima, Tsutomu
    Minashi, Keiko
    Komatsu, Yoshito
    Nishina, Tomohiro
    Nakajima, Takako Eguchi
    Sahara, Takatoshi
    Funasaka, Setsuo
    Yashiro, Masakazu
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Garmezy, B.
    Borad, M.
    Lin, C. C.
    Chen, L. T.
    Perez, C. A.
    Kato, S.
    Tam, B.
    Severson, P.
    Quah, C. S.
    Harding, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
12345